| [1] |
Ebrahimi F, Gopalan V, Smith RA，et al. miR-126 in human cancers：clinical roles and current perspectives[J]. Exp Mol Pathol，2014，96(1):98-107.
|
| [2] |
Dzikiewicz-Krawczyk A, Macieja A, Mały E，et al. Polymorphisms in microRNA target sites modulate risk of lymphoblastic and myeloid leukemias and affect microRNA binding[J]. J Hematol Oncol，2014(7):43.
|
| [3] |
Kong YW, Ferland-Mccollough D, Jackson TJ，et al. microRNAs in cancer management[J]. Lancet Oncol，2012，13(6):e249-e258.
|
| [4] |
Garofalo M, Quintavalle C, Romano G，et al. miR221/222 in cancer：their role in tumor progression and response to therapy[J]. Curr Mol Med，2012，12(1):27-33.
|
| [5] |
Zhang J, Han L, Ge Y，et al. miR-221/222 promote malignant progression of glioma through activation of the Akt pathway[J]. Int J Oncol，2010，36(4):913-920.
|
| [6] |
Zhang CZ, Zhang JX, Zhang AL，et al. MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma[J]. Mol Cancer，2010(9):229.
|
| [7] |
Di Martino MT, Gullà A, Cantafio ME，et al. In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma[J]. Oncotarget，2013，4(2):242-255.
|
| [8] |
Zhang CZ, Han L, Zhang AL，et al. MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN[J]. BMC Cancer，2010(10):367.
|
| [9] |
Di Leva G, Gasparini P, Piovan C，et al. MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer[J]. J Natl Cancer Inst，2010，102(10):706-721.
|
| [10] |
Sun T, Yang M, Chen S，et al. The altered expression of MiR-221/-222 and MiR-23b/-27b is associated with the development of human castration resistant prostate cancer[J]. Prostate，2012，72(10):1093-1103.
|
| [11] |
Ogawa T, Enomoto M, Fujii H，et al. MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis[J]. Gut，2012，61(11):1600-1609.
|
| [12] |
O′Hara AJ, Wang L, Dezube BJ，et al. Tumor suppressor microRNAs are underrepresented in primary effusion lymphoma and Kaposi sarcoma[J]. Blood，2009，113(23):5938-5941.
|
| [13] |
Liu X, Yu J, Jiang L，et al. MicroRNA-222 regulates cell invasion by targeting matrix metalloproteinase 1（MMP1）and manganese superoxide dismutase 2（SOD2）in tongue squamous cell carcinoma cell lines[J]. Cancer Genomics Proteomics，2009，6(3):131-139.
|
| [14] |
Okamoto K, Miyoshi K, Murawaki Y. miR-29b，miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells[J]. PLoS ONE，2013，8(10):e77623.
|
| [15] |
Castagnino P, Kothapalli D, Hawthorne EA，et al. miR-221/222 compensates for Skp2-mediated p27 degradation and is a primary target of cell cycle regulation by prostacyclin and cAMP[J]. PLoS One，2013，8(2):e56140.
|
| [16] |
Zhong C, Ding S, Xu Y，et al. MicroRNA-222 promotes human non-small cell lung cancer H460 growth by targeting p27[J]. Int J Clin Exp Med，2015，8(4):5534-5540.
|
| [17] |
Sarkar S, Dubaybo H, Ali S，et al. Down-regulation of miR-221 inhibits proliferation of pancreatic cancer cells through up-regulation of PTEN，p27kip1，p57kip2，and PUMA[J]. Am J Cancer Res，2013，3(5):465-477.
|
| [18] |
Hikisz P, Kiliańska ZM. PUMA，a critical mediator of cell death—one decade on from its discovery[J]. Cell Mol Biol Lett，2012，17(4):646-669.
|
| [19] |
Zhang C, Zhang J, Zhang A，et al. PUMA is a novel target of miR-221/222 in human epithelial cancers[J]. Int J Oncol，2010，37(6):1621-1626.
|
| [20] |
Jiang F, Zhao W, Zhou L，et al. miR-222 regulates the cell biological behavior of oral squamous cell carcinoma by targeting PUMA[J]. Oncol Rep，2014，31(3):1255-1262.
|
| [21] |
Jiang F, Zhao W, Zhou L，et al. MiR-222 Targeted PUMA to improve sensitization of UM1 cells to cisplatin[J]. Int J Mol Sci，2014，15(12):22128-22141.
|
| [22] |
Zheng C, Yinghao S, Li J. MiR-221 expression affects invasion potential of human prostate carcinoma cell lines by targeting DVL2[J]. Med Oncol，2012，29(2):815-822.
|
| [23] |
Stinson S, Lackner MR, Adai AT，et al. TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer[J]. Sci Signal，2011，4(177):ra41.
|
| [24] |
Zhang C, Zhang J, Hao J，et al. High level of miR-221/222 confers increased cell invasion and poor prognosis in glioma[J]. J Transl Med，2012(10):119.
|
| [25] |
Urbich C, Kuehbacher A, Dimmeler S. Role of microRNAs in vascular diseases，inflammation，and angiogenesis[J]. Cardiovasc Res，2008，79(4):581-588.
|
| [26] |
Chen WX, Hu Q, Qiu MT，et al. miR-221/222：promising biomarkers for breast cancer[J]. Tumor Biol，2013，34(3):1361-1370.
|
| [27] |
Rippe C, Blimline M, Magerko KA，et al. MicroRNA changes in human arterial endothelial cells with senescence：relation to apoptosis，eNOS and inflammation[J]. Exp Gerontol，2012，47(1):45-51.
|
| [28] |
Liu X, Cheng Y, Yang J，et al. Cell-specific effects of miR-221/222 in vessels：molecular mechanism and therapeutic application[J]. J Mol Cell Cardiol，2012，52(1):245-255.
|
| [29] |
Magee P, Shi L, Garofalo M. Role of microRNAs in chemoresistance[J]. Ann Transl Med，2015，3(21):332.
|
| [30] |
Gan R, Yang Y, Yang X，et al. Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3[J]. Cancer Gene Ther，2014，21(7):290-296.
|
| [31] |
Wei Y, Lai X, Yu S，et al. Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells[J]. Breast Cancer Res Treat，2014，147(2):423-431.
|
| [32] |
Chen L, Zhang J, Han L，et al. Downregulation of miR-221/222 sensitizes glioma cells to temozolomide by regulating apoptosis independently of p53 status[J]. Oncol Rep，2012，27(3):854-860.
|
| [33] |
Li W, Guo F, Wang P，et al. miR-221/222 confers radioresistance in glioblastoma cells through activating Akt independent of PTEN status[J]. Curr Mol Med，2014，14(1):185-195.
|
| [34] |
Kim SY, Nam SY, Choi S，et al. Prognostic value of lymph node density in node-positive patients with oral squamous cell carcinoma[J]. Ann Surg Oncol，2011，18(8):2310-2317.
|
| [35] |
DE Lima PO, Jorge CC, Oliveira DT，et al. Hypoxic condition and prognosis in oral squamous cell carcinoma[J]. Anticancer Res，2014，34(2):605-612.
|
| [36] |
Gombos K, Horváth R, Szele E，et al. miRNA expression profiles of oral squamous cell carcinomas[J]. Anticancer Res，2013，33(4):1511-1517.
|
| [37] |
Yang CJ, Shen WG, Liu CJ，et al. miR-221 and miR-222 expression increased the growth and tumorigenesis of oral carcinoma cells[J]. J Oral Pathol Med，2011，40(7):560-566.
|
| [38] |
江方方，赵玮，胡逢春，等.反义miR-222靶向上调PUMA基因表达促进口腔鳞状细胞癌凋亡[J/CD].中华口腔医学研究杂志：电子版，2013，7(3):201-206.
|
| [39] |
Jiang F, Zhao W, Zhou L，et al. miR-222 regulates the cell biological behavior of oral squamous cell carcinoma by targeting PUMA[J]. Oncol Rep，2014，31(3):1255-1262.
|
| [40] |
周李杰，赵玮，江方方，等.微小RNA-221/222海绵体载体的构建及验证[J/CD].中华口腔医学研究杂志：电子版，2015，9(2):106-112.
|
| [41] |
Vávrová J, Rezáčová M. Importance of proapoptotic protein PUMA in cell radioresistance[J]. Folia Biol（Praha），2014，60(2):53-56.
|
| [42] |
Li W, Guo F, Wang P，et al. miR-221/222 confers radioresistance in glioblastoma cells through activating Akt independent of PTEN status[J]. Curr Mol Med，2014，14(1):185-195.
|